ABSTRACT
O objetivo deste estudo foi comparar as duas apresentações de GH recombinante humano (rGH) para tratamento da deficiência de GH (DGH). Dez crianças pré-púberes portadoras de DGH foram acompanhadas durante 6 meses. Elas receberam, por 3 meses, injeções com seringa e, a seguir, com canetas por mais 3 meses. A aceitabilidade foi avaliada através de questionário. O desperdício foi calculado através da diferença entre o número de frascos/refis utilizados e o previsto para o período. A resposta ao tratamento foi avaliada pelo ganho em desvio-padrão (DP) de altura medido a cada 3 meses. Após 6 meses, 90 por cento dos pacientes/familiares afirmaram preferir a caneta em termos de facilidade técnica e dor local, e todos consideraram a caneta melhor em termos de facilidade de transporte e armazenamento. O desperdício foi menor com a caneta, assim como o custo. Concluímos que a administração de rGH através de caneta é mais conveniente, melhor aceita pelos pacientes e resulta em menor desperdício quando comparada com o tratamento por seringa.
The aim of this study was to compare two preparations of recombinant human GH (rGH) in the treatment of GH deficient patients. Ten prepubertal GH-deficient children were followed during 6 months. They received injections with syringe for 3 months, followed by pen administration for the subsequent 3 months. Acceptability was evaluated through a questionnaire. Waste of medication was calculated by the difference between the number of used bottles or refills and the calculated amount for the period. Treatment response was evaluated by SDS gain of height measured each 3 months. After 6 months, 90 percent of patients/family members declared they preferred the pen regarding technical facility and local pain, and all patients considered the pen easier to transport and store. The waste of medication was lower with pen administration, as was the final cost. We concluded that pen-administered rGH treatment is more convenient, better accepted by the patients, and leads to less waste of medication when compared to the syringe administration.
Subject(s)
Child , Female , Humans , Male , Growth Disorders/drug therapy , Human Growth Hormone/administration & dosage , Injections , Patient Acceptance of Health Care , Syringes , Drug Storage/standards , Family , Follow-Up Studies , Human Growth Hormone/blood , Human Growth Hormone/deficiency , Injections/economics , Self Administration/instrumentation , Syringes/economicsABSTRACT
The burden of disease associated with unsafe therapeutic injection practices in Pakistan is very high. The number of injection per person per year has been estimated to be in the range of 8.2 to 13.6, one of the highest in developing world. Extrapolating this number to the whole country would result in 1.5 billion injections per year. Approximately 4% [75 million] of these are administered for immunization while the remainders are used for therapeutic use. Of these, 94.2% are unnecessary. Average price of an injection [not the complete prescription] is Rs. 20.6 [US$ 0.34]. Under conservative estimate, over three billion rupees or 500 million dollars outof- pocket healthcare resources may be wasted each year. Appropriate use of injections would be highly cost effective. According to adjusted analysis, safe and appropriate use of injection in Pakistan would cost US$ 92 million each year with a high proportion that would be injection devices paid through out-of-pocket expenses. Behaviour change for reduction in number of injections require long-term multidimentional efforts. Interventions in the form of phasing out of convention disposable injection equipment and switching to reuse prevention devices for all injections could prevent the common practice of reuse, hence reducing the transmission of infections